[HTML][HTML] Molnupiravir and its antiviral activity against COVID-19
L Tian, Z Pang, M Li, F Lou, X An, S Zhu… - Frontiers in …, 2022 - frontiersin.org
The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) constitutes a major worldwide public health threat …
syndrome coronavirus 2 (SARS-CoV-2) constitutes a major worldwide public health threat …
Molnupiravir: A new candidate for COVID‐19 treatment
F Pourkarim, S Pourtaghi‐Anvarian… - Pharmacology …, 2022 - Wiley Online Library
The novel coronavirus disease 2019 (COVID‐19) emerged in late December 2019 in china
and has rapidly spread to many countries around the world. The effective pharmacotherapy …
and has rapidly spread to many countries around the world. The effective pharmacotherapy …
[HTML][HTML] Repurposing molnupiravir for COVID-19: the mechanisms of antiviral activity
Molnupiravir is a β-d-N4-hydroxycytidine-5′-isopropyl ester (NHC) compound that exerts
antiviral activity against various RNA viruses such as influenza, SARS, and Ebola viruses …
antiviral activity against various RNA viruses such as influenza, SARS, and Ebola viruses …
[HTML][HTML] Molnupiravir—a novel oral anti-SARS-CoV-2 agent
Since December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has
rapidly resulted in a global pandemic with approximately 4 million deaths. Effective oral …
rapidly resulted in a global pandemic with approximately 4 million deaths. Effective oral …
Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19
GR Painter, MG Natchus, O Cohen, W Holman… - Current opinion in …, 2021 - Elsevier
Highlights•Molnupiravir is a broad acting, oral antiviral versus SARS-CoV-2, flu, Ebola and
others.•Clinical development was greatly accelerated in response to the COVID19 …
others.•Clinical development was greatly accelerated in response to the COVID19 …
[HTML][HTML] Discovery, development, and patent trends on molnupiravir: a prospective oral treatment for COVID-19
The COVID-19 pandemic needs no introduction at present. Only a few treatments are
available for this disease, including remdesivir and favipiravir. Accordingly, the …
available for this disease, including remdesivir and favipiravir. Accordingly, the …
[HTML][HTML] Efficacy and safety of Molnupiravir in COVID-19 patients: A systematic review
Background Molnupiravir is an oral antiviral drug that received Emergency Use
Authorization in three countries for the treatment of mild COVID-19. The aim of this …
Authorization in three countries for the treatment of mild COVID-19. The aim of this …
[HTML][HTML] The pill of recovery; Molnupiravir for treatment of COVID-19 patients; a systematic review
Background Throughout the time of the global pandemic of SARS-CoV-2 virus, there has
been a compelling necessity for the development of effective antiviral agents and …
been a compelling necessity for the development of effective antiviral agents and …
Efficacy and safety of molnupiravir treatment for COVID-19: a systematic review and meta-analysis of randomized controlled trials
F Tian, Q Feng, Z Chen - International Journal of Antimicrobial Agents, 2023 - Elsevier
Introduction There are currently some differences in the research results of molnupiravir.
This study aimed to evaluate the efficacy and safety of molnupiravir in the treatment of …
This study aimed to evaluate the efficacy and safety of molnupiravir in the treatment of …
Human safety, tolerability, and pharmacokinetics of molnupiravir, a novel broad-spectrum oral antiviral agent with activity against SARS-CoV-2
WP Painter, W Holman, JA Bush… - Antimicrobial agents …, 2021 - Am Soc Microbiol
ABSTRACT Molnupiravir (EIDD-2801/MK-4482), the prodrug of the active antiviral
ribonucleoside analog β-d-N4-hydroxycytidine (NHC; EIDD-1931), has activity against a …
ribonucleoside analog β-d-N4-hydroxycytidine (NHC; EIDD-1931), has activity against a …